Neonatal hyperbilirubinemia.
D000138:Acidosis / Q000517:prevention & control; D000362:Agar / Q000627:therapeutic use; D000743:Anemia, Hemolytic / Q000150:complications; D000906:Antibodies / Q000008:administration & dosage; D001663:Bilirubin / Q000378:metabolism; D001787:Blood Group Incompatibility; D001805:Blood Transfusion, Intrauterine; D005078:Exchange Transfusion, Whole Blood; D005260:Female; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000150:complications; D006801:Humans; D006932:Hyperbilirubinemia / Q000150:complications / Q000209:etiology / Q000628:therapy; D007003:Hypoglycemia / Q000517:prevention & control; D000860:Hypoxia / Q000517:prevention & control; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases; D010634:Phenobarbital / Q000627:therapeutic use; D011247:Pregnancy; D011485:Protein Binding; D011770:Pyruvate Kinase / Q000378:metabolism; D012204:Rh-Hr Blood-Group System; D012709:Serum Albumin
D000906:Antibodies; D012204:Rh-Hr Blood-Group System; D012709:Serum Albumin; D000362:Agar; D011770:Pyruvate Kinase; D001663:Bilirubin; D010634:Phenobarbital